Dr. Apple wants to study a drug to manage diabetes in adolescents. The researcher plans…
- User
Dr. Apple wants to study a drug to manage diabetes in adolescents. The researcher plans to use an electronic informed consent (eIC) form presented on a tablet device. Per FDA guidance on the “Use of Electronic Consent in Clinical Investigations” (2016), can adolescent subjects assent using an electronic device? No, the eIC cannot be used for assent from pediatric subjects No, the eIC cannot be used because this is a FDA-regulated clinical investigation Yes, the eIC process can be used for assent Yes, the eIC process can be used but only if the subject can sign their own name electronically
Assistant
The correct answer is:
Yes, the eIC process can be used for assent.
Explanation:
According to the FDA guidance on the "Use of Electronic Informed Consent in Clinical Investigations" (2016), electronic informed consent (eIC) can be used in clinical investigations, including obtaining assent from adolescent subjects. The guidance does not prohibit the use of eIC for pediatric populations or for assent specifically.
Here are the key points to consider:
-
Assent vs. Consent:
- Assent refers to the agreement of a minor or person who is not legally authorized to provide consent to participate in a study. Assent must be obtained in addition to parental permission when dealing with pediatric subjects.
- Consent, on the other hand, is the legal authorization provided by a participant or their legally authorized representative (LAR).
-
FDA Guidance on eIC:
- The FDA allows the use of electronic methods to obtain both consent and assent, as long as the process complies with regulatory requirements.
- The guidance emphasizes that the eIC process must ensure that participants (or their representatives) understand the information presented and that the system is secure, accessible, and user-friendly.
-
Key Considerations for eIC in Pediatric Studies:
- For adolescent subjects, the eIC process can be adapted to their level of understanding, just as it would be with traditional paper-based assent forms.
- The FDA does not require a specific method for signing electronically (e.g., typing a name, using a stylus, or other electronic signatures). Therefore, the subject does not necessarily need to sign their own name electronically as long as the system captures their agreement appropriately.
-
Misconceptions in Other Options:
- "No, the eIC cannot be used for assent from pediatric subjects": This is incorrect because the FDA guidance explicitly permits the use of eIC for assent, provided it meets regulatory standards.
- "No, the eIC cannot be used because this is an FDA-regulated clinical investigation": This is incorrect because the FDA supports the use of eIC in regulated clinical investigations, including those involving minors.
- "Yes, the eIC process can be used but only if the subject can sign their own name electronically": This is incorrect because the FDA does not mandate a specific method of electronic signature for assent or consent.
Conclusion:
The eIC process can be used for assent in pediatric populations, including adolescents, as long as the process complies with applicable regulations and ensures that the subject understands the study and agrees to participate.
-
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.